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Abstract  
The growth and survival of multi-cellular organisms depends upon their abilities to acquire 
and metabolize nutrients, efficiently store and harness energy, and sense and fight infection. 
Systems for sensing and using nutrients have consequently co-evolved alongside systems for 
sensing and responding to pathogens and other danger signals, and share many of the same 
cell signaling proteins and networks. Hypercaloric diets high in fats and carbohydrates can 
overload these systems, leading to obesity, metabolic dysfunction, impaired immunity, and 
cardiovascular disease. Excessive nutrient intake promotes adiposity, typically altering 
adipocyte function and immune cell distribution, both of which trigger metabolic 
dysfunction. Here we discuss novel mechanistic links between metabolism and immunity that 
underlie metabolic dysfunction in obesity. We aim to stimulate debate about how the 
endocrine and immune systems are connected through autocrine, paracrine and 
neuroendocrine signaling in sophisticated networks that are only now beginning to be 
resolved. Understanding the expression and action of signaling proteins, and modulating their 
receptors or pattern recognition by agonists or antagonists, may resolve whether intervention 
in immunometabolism can lead to novel treatments for obesity and metabolic dysfunction. 
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Obesity, inflammation, and metabolic dysfunction 
Obesity is defined as abnormal or excessive fat accumulation and is increasingly a major 
cause of human morbidity and mortality in most societies (1-3). Clinical features of obesity 
combined with hyperglycemia, hyperlipidemia, and hypertension are now collectively termed 
the ‘metabolic syndrome’. The resulting abnormalities in glucose, lipid, and fluid 
homeostasis increase the risk of Type 2 diabetes and cardiovascular disease (4,5). Obesity is 
considered to be a low-grade chronic inflammatory condition (3), and involves sophisticated 
interplay between metabolic and immune systems. This concept is highlighted by 
observational links between healthy diet and successful protective immunity, and between 
chronic malnutrition and low immunity (1,3). However, many key issues remain unresolved. 
An important question is whether inflammatory stress leads to adiposity and metabolic 
disease, or whether adiposity leads to inflammatory responses that initiate or exacerbate 
metabolic dysfunction, or whether they stimulate each other. Metabolic dysfunction can 
result from inflammation-induced cellular damage (3,6,7), but conversely inflammation can 
also be initiated and sustained by chronic energy overload inducing cellular stress such as 
mitochondrial dysfunction, endoplasmic reticulum stress and increased production of reactive 
free radicals (8-10). Metabolic disease, which initiates inflammation and lipid accumulation 
in the liver, may occur in pre-obese states without evident systemic inflammation (11). 
Inflammation in metabolic dysfunction appears to be initiated in the liver, followed by 
adipocyte dysfunction and then muscle insulin resistance (12). Yet other studies show that 
high fat diets induce oxidative and inflammatory responses in healthy lean people and some 
patients with chronic inflammatory diseases develop metabolic disease, supporting the notion 
that inflammatory stress precedes metabolic disease (7). Furthermore, obesity without 
metabolic dysfunction (‘fit fat’) is not uncommon and, conversely, some lean people have 
severe metabolic disease (13). Thus, instead of one initiating the other, these observations 
hint that energy-demanding processes such as recognition, absorption, storage, and 
metabolism of host energy supply may be entangled with mechanisms for immune defense 
and ‘danger sensing’. We speculate that a balanced energy flux and maintenance of favorable 
metabolic homeostasis is required for the proper functioning of the immune system, since 
initiation and maintenance of immunity is a metabolically expensive process and cannot 
function effectively or for very long during energy surplus or deficiency. 
 
Inflammation is succinctly defined as an acute physiological response to infection or injury, 
involving coordination of many complex signals in distinct cells and organ systems to negate 
and remove the source of infection and to repair tissue injury (14). When this response does 
not remove the inflammatory stimulus or resolve the damage, it becomes prolonged and leads 
to characteristic pathologies. In metabolic disease, the prolonged response becomes a low 
grade chronic inflammation, sustained by nutritional and metabolic surplus using a similar set 
of molecules and signaling pathways as inflammatory responses to infection (15). Unlike the 
inflammatory response to infection, the inflammation in metabolic disease is geared to 
regulating endogenous nutrient metabolism and exogenous nutrient intake (1). The innate-
immune molecules and pathways alter responses in many organ systems that collaborate in 
the recognition, absorption, storage, and metabolism of surplus energy supply. These 
differences emphasize that systemic inflammation is not a useful measure of the low-grade 
inflammation in metabolic disease, and highlight that these organ systems and signaling 
pathways were co-developed to coordinate metabolism with immunity. The study of this 
interface is now referred to as ‘immunometabolism’ (16-18) and identifying novel therapeutic 
opportunities relies on the detailed understanding, usage, and interpretation of this concept. 
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Nutrient sensing and energy homeostasis 
Claude Bernard in 1865 and Walter Cannon in 1926 described the essential concept of 
homeostasis – the body’s ability to achieve and maintain a stable internal environment. They 
suggested that multiple mechanisms contribute to dynamic equilibria that regulate the balance 
between nutrient intake and energy use in all living organisms. In general, free energy in 
multi-cellular organisms is traded in adenosine triphosphate (ATP). Food is converted into 
nutrients such as glucose, free fatty acids, and amino acids. These nutrients are either directly 
metabolised to ATP or stored as lipids, glycogen or proteins that are later metabolised to ATP 
via relatively energy-expensive catabolic processes. When an organism encounters excess 
energy as food, it conserves the nutrients either as glycogen for short-term storage, or as 
lipids for longer storage duration and lipid combustion as a higher energy source (3). During 
evolution, limited or spasmodic nutrient supply forced organisms to manage the need for 
portable energy with the need to store fatty acids efficiently, and to develop effective 
transcriptional machineries such as PPARs and NFkB that are activated by fatty acids to 
regulate cellular responses, physiological processes, and immune defence (3). However, 
dietary calories are no longer limited for most individuals in the 21st century, and this has led 
to an epidemic of obesity and associated metabolic disturbances. Energy homeostasis relies 
upon controlling the balance between glucose and lipid storage with energy usage. When this 
balance is disrupted or impaired, it can lead to hyperglycemia, hyperlipidemia, and 
hyperphagia. In obesity, the efficiency of lipid to ATP conversion may become 
compromised, so that obese individuals have a deficit of energy in the form of ATP with 
simultaneous over-synthesis and storage of lipids resulting in excess adiposity. In obese 
patients, the induction of a negative energy balance, that is, consuming fewer calories than 
expended, improves metabolic abnormalities prior to significant reduction in the excess fat 
storage.  
 
Energy, lipid, and glucose homeostasis are achieved by a balance between food intake and 
energy expenditure, as well as fatty acid and glucose production and utilization. In humans, 
there is a complex nutrient sensing system for balancing hunger and satiety, set against an 
obvious survival genetic background of opportunistically increasing energy storage. This 
involves recognising nutrients in the gut and absorbing them, and sensing whether to 
metabolise or store these nutrients in adipose and other peripheral tissues. Here we describe a 
working hypothesis whereby a chronic increase in macronutrients disrupts normal nutrient 
sensing and triggers neuronal negative feedback mechanisms, involving signaling molecules 
that have traditionally been seen to play immune roles, in order to maintain metabolic 
homeostasis. In particular, we will discuss how disruption of nutrient sensing in the gut and 
the brain trigger neuronal and immune networks to regulate nutrient intake, storage, and 
metabolism in adipose and peripheral tissues such as pancreas, muscle, and liver to alter 
energy homeostasis in obesity and metabolic dysfunction. This model provides a framework 
to identify novel therapeutic strategies targeting peripheral neural and immune signaling to 
restore energy, lipid, and glucose homeostasis in metabolic disease. 
 
The central nervous system (CNS) is critical for mediating the systemic nutrient sensing 
mechanisms by activating neural networks as negative feedback systems, the gut-brain, gut-
pancreas, brain-adipose, and gut-brain-liver axes thereby regulating energy, fatty acid, and 
glucose homeostasis (Figure 1) (19,20). Nutrient or lipid sensing within the intestine, or 
locally in the brain, triggers the CNS to reduce food intake and hepatic glucose production, 
and this helps to maintain glucose and energy homeostasis. Further, nutrient sensing within 
the gut triggers the secretion of incretins, involving the gut-pancreas axis to regulate whole 
body glucose homeostasis (21). Parallel sensing and metabolism of nutrients within the 
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hypothalamus regulates food intake and circulating fatty acid and glucose concentrations 
through regulatory hormones, including leptin, insulin, adiponectin, orexin, ghrelin, 
melanocortins and neuropeptide Y (19-24). This review aims to stimulate discussion by 
presenting some mechanistic associations and hypotheses on the complex network between 
the endocrine and the danger sensing systems, and how the endocrine system relies on 
autocrine, paracrine, and neuroendocrine signaling of the danger sensing system to regulate 
energy homeostasis in metabolically relevant tissues.  
   
Nutrient regulation by the CNS  
The ability to adjust food intake in response to changing energy requirements and 
environmental conditions is essential for an organism to survive and adapt to its conditions 
(25). The CNS receives and processes complex information from cognitive, visual and 
olfactory cues in order to make an overall assessment of food availability and palatability 
before responding by emitting regulatory signals geared to manage digestion, absorption, 
nutrient transport, and storage (25). Integration of these signals is important for controlling 
appetite, so that food consumed does not exceed what can be safely managed and, 
conversely, that energy demands do not exceed energy supply (25). Many blood-borne and 
afferent neural regulatory signals communicate with the brain to adjust food intake and fat 
storage over time (24,25). The motivation to consume food and the amount tends to increase 
until energy stores are replenished, and disruption of any of the regulatory hormonal signals 
such as ghrelin, leptin, orexin, or adiponectin induces obesity or appetite suppression in 
animal models and humans (24). Current evidence indicates that nutrient or lipid sensing 
within the intestine or locally in the brain triggers the CNS to reduce food intake and hepatic 
glucose production, which helps to maintain glucose and energy homeostasis. Conversely, 
appetite and food intake are automatically stimulated by energy losses via the gastrointestinal 
and/or renal tract or through intense physical activity. 
 
Apart from participating in the hormonal regulation of hunger and satiety, the brain can 
recognise and detect subtle local changes in nutrient concentrations, resulting in signaling to 
the periphery to change hepatic glucose production and food intake to maintain homeostasis 
(19,25). However, the precise non-hormonal mechanisms by which the brain regulates this 
glucose and energy homeostasis in humans are not currently known. Mechanistic studies in 
rodent models suggest that hypothalamic fatty acid metabolism helps to mediate actions of 
leptin and ghrelin that regulate hunger and satiety, with involvement of protein kinase C 
(PKC) isoforms together with fatty acids and enzymes, involved in inflammation and fatty 
acid metabolism, known to impair insulin signaling in liver and muscle (19,26,27). 
Hypothalamic PKC-θ activated by palmitic acid impairs central actions of regulators of 
energy homeostasis such as leptin and insulin (19,28). Knocking down hypothalamic PKC-θ 
restores otherwise impaired insulin action and glucose intolerance in diet-induced obesity 
(19,28). Hypothalamic PKC-δ activation by lipids (23) decreases hepatic glucose production, 
but no studies have evaluated the lowering of hepatic glucose production or food intake by 
direct activation of PKC isoforms in the hypothalamus (19). High-fat feeding impairs the 
ability of long-chain fatty acid-CoA in the hypothalamus to lower hepatic glucose production 
(29-32). Inhibition of hypothalamic enzymes involved in fatty acid metabolism such as 
carnitine palmitoyltransferase-1 restores long-chain fatty acid-CoA, thereby improving 
glucose homeostasis impaired by high-fat feeding (19,29,30). Genetic deletion of 
hypothalamic fatty acid synthase also lowers hepatic glucose production and restores 
hypothalamic lipid sensing mechanisms in high-fat fed mice (19). Hypothalamic fatty acid 
metabolism plays an important role in mediating the actions of leptin (31) and ghrelin (32) to 
regulate hunger and satiety. The ability of ghrelin or leptin to regulate glucose homeostasis 
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may be regulated through the central fatty acid metabolic network, given that fatty acid 
metabolism in the hypothalamus is important in peripheral glucose regulation (19). Thus, 
both local sensing and direct metabolism of certain nutrients such as fatty acids within the 
hypothalamus together may regulate food intake and blood glucose concentration. Since fatty 
acids can play immune roles, further studies into whether fatty acid metabolism is 
dysregulated due to altered immune sensing is necessary to tease out non-hormonal 
mechanisms by which the brain regulates this glucose and energy homeostasis (33). 
 
Nutrient sensing, recognition and absorption by the gut  
Similar to the brain, local sensing of nutrients in the intestine activates a gut-brain signaling 
axis to regulate energy homeostasis, and a gut-brain-liver and gut-pancreas signaling axis to 
regulate glucose homeostasis (19). Lipid sensing in the intestine activates neuronal negative 
feedback systems to regulate peripheral glucose homeostasis, whereas it triggers a more 
central mechanism to regulate energy homeostasis (19). In general, food is broken down into 
nutrients that are then transported through the cells of the intestine and passed on to the 
circulation. However, lipids inside the gut can inhibit food intake in rats and humans (34,35). 
Lipids synthesized in the intestine, such as oleoylethanolamide and N-
acylphosphatidylethanolamine, act on the CNS to reduce food intake (36,37). Further, dietary 
lipids modulate ghrelin activation and acylation to increase food intake through neural 
networks (38,39). Intestinal lipids stimulate the release of cholecystokinin from intestinal 
cells while activation of cholecystokinin-A receptors triggers a gut-brain signaling axis to 
lower food intake (40). Further, cholecystokinin and other enterohormones such as incretins 
trigger a gut-pancreas axis to control glucose homeostasis and appetite via both neural and 
direct hormonal mechanisms (41). Intestinal lipid sensing regulates glucose homeostasis, 
shown by improved glucose metabolism in diabetic patients following gastric bypass surgery 
before substantial weight loss (19,42,43). However, this is still debatable as gastric bypass 
surgery suppresses appetite and similar effects could be mimicked by caloric restriction (44). 
Nonetheless, nutrient sensing in the intestine could be enhanced after gastric bypass surgery 
or caloric restriction to lower hepatic glucose production by triggering a portal vein-brain-
liver axis (45) and a portal vein-brain-muscle axis to regulate glucose uptake in the muscle 
under hyperinsulinemic conditions (46,47). A further example of multi-tissue integration of 
energy handling is the recent recognition of free fatty acids and bile acids as signaling 
molecules, acting via TGR5 and GPR40 receptors respectively, to promote post-prandial 
energy management. 
 
Clearly, a better understanding will be gained by identifying the underlying mechanisms that 
define how intestinal nutrient sensing and caloric restriction trigger neural networks to 
communicate with the brain and peripheral tissues. Recent evidence from animal studies 
suggests that dysfunction or disruption of the body’s danger sensing system including Toll-
like receptor (TLR) signaling and gut microflora can increase food intake and induce insulin 
resistance, metabolic dysfunction, and obesity in mice (6,48-50). There are some obvious 
questions to be asked, including whether the increase in food intake occurs through a gut-
brain axis; if so, the role of TLR signaling, as the major danger sensor, to regulate this gut-
brain axis in order to maintain energy homeostasis needs to be clarified. The CNS and the 
immune system have traditionally been considered as separate entities and their interaction 
and communication has been thought to occur as a result of dysfunctional systems. However, 
emerging evidence suggests that TLRs are likely to be an integral component in the 
communication between the CNS and the periphery in neurodegenerative diseases (49,50). 
Since these pattern recognition receptors are also involved in initiation and progression of 
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metabolic disease (10), they may facilitate communication between the CNS and the 
periphery to regulate metabolism.  
 
Pathogen and danger sensing 
The origin of inflammation in obesity and metabolic disease, either infectious or non-
infectious or both, is still debatable. Nutrient intake continuously exposes the GI tract to new 
and potentially harmful microbes, although many microbiota already cohabit peacefully in 
the gut and contribute beneficially to immunity and homeostasis. Perturbations in these 
symbiotic relationships can distort both immune and nutrient sensing mechanisms. Immune 
defence against infection in the gut is similar to immune mechanisms elsewhere. In 
mammals, the danger sensing system is equipped with pattern recognition receptors such as 
the TLRs as well as the nucleotide-binding oligomerisation domain proteins (NODs) (51). 
These receptors initiate downstream signaling pathways to express proinflammatory 
cytokines required for host defence (51). An active danger sensing system in metabolically 
relevant tissues including the intestine, adipose, brain, and immune cells suggests a much 
more complex and intertwined relationship between sensing systems (Figure 2). The innate 
immune system reacts to pathogen-associated molecular patterns during infection, as well as 
other sets of conserved endogenous molecules released after cellular stress referred to as 
damage-associated molecular patterns. The latter compounds signal through the same pattern 
sensing receptors to initiate a response even in the absence of pathogens (52). Circulating 
mitochondrial damage-associated molecular patterns, including formyl peptides and 
mitochondrial DNA, induce inflammatory responses to injury (9). The immune response is 
perpetuated by advanced glycation end products acting on the Receptor for Advanced 
Glycation Endproducts (RAGE) (53). Whether metabolic dysfunction is induced via these 
molecules through mitochondrial dysfunction is not known. Furthermore, complex 
communication between gut microbiota and the innate immune system through TLRs may 
help maintain metabolic homeostasis (6,48,54). These observations further substantiate the 
idea that metabolic and immune regulatory mechanisms interact in human metabolic disease 
and metabolic dysfunction possibly as a result of both external and internal triggers, both 
pathogen-associated and damage-associated molecular patterns, signaling through the body’s 
danger sensing mechanisms to induce a chronic inflammatory state. TLRs are key suspects 
given their precursor status to both infection-induced (microbiota) and non-infectious sterile 
inflammatory pathways by endogenous molecules produced during tissue/cellular stress, and 
also saturated fatty acids such as lauric and palmitic acids from modern diets (51). 
 
Nutrient and danger sensing cooperate in energy homeostasis and immunity  
Nutrient and danger sensing mechanisms influence one another in contributing to regulation 
of energy homeostasis. Nutrients such as lipids and carbohydrates regulate both energy 
requirements and danger sensing signaling. A balanced energy flux and maintenance of 
metabolic homeostasis is clearly required for effective functioning of the immune system (1). 
The gastrointestinal tract plays important roles in immunity, with its large surface area 
continuously exposed to many microbes and food making it a unique interface between 
nutrient sensing, absorption, and the danger sensing system (55,56). The Bacteroidetes and 
the Firmicutes constitute over 90% of the microbes present in the distal gut (56). Gut 
microbes contribute towards breakdown and energy extraction from food. The gut microbiota 
are also involved in the development of obesity, metabolic disease, and associated 
inflammation. Changes in the gut microbiome have been implicated in diseases such as colon 
cancer, inflammatory bowel diseases, Type 1 diabetes (56-58) and obesity, since such 
changes may enhance energy extraction from the diet (58). Further, damage to gut barrier 
function following changes to the microbiota may increase blood concentrations of 
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endotoxins such as lipopolysaccharide (LPS) from gut bacteria that trigger obesity-associated 
inflammation (59). These endotoxins could supply the infectious sources of low-grade 
inflammation in obesity, acting together with dietary saturated fatty acids to initiate innate 
immune responses. This concept has been supported by studies in human patients and knock-
out mice, such as those described below.  
 
Some human studies in lean, obese and Type 2 diabetic patients report that high fat meals can 
induce postprandial increases in plasma LPS concentrations leading to low grade 
inflammation (7, 60-62). In rodent models of diet-induced obesity, TLR4 knockout prevents 
saturated fat-induced weight gain and obesity-related inflammation (63). Selective 
knockdown of TLR4 in hepatocytes prevents obesity-induced inflammation and insulin 
resistance without affecting body weight in diet-induced obese mice (64). Furthermore, 
intracerebroventricular administration of TLR4 neutralising antibody prevents hypothalamic 
inflammation, defective liver gluconeogenesis and hyperglycemia, validating a TLR4-
mediated brain-liver axis in regulating glucose homeostasis (65). Pharmacological 
antagonism of TLR4 also prevents the progression of kidney disease in diet-induced obese 
mice (66). Other TLRs may also be activated by dietary lipids, as specific knockdown of 
hypothalamic neural TLR2 protects also against both mature-onset age-induced and high fat-
induced obesity in mice (67). Taken together, these studies suggest that diet-induced obesity, 
insulin and leptin resistance may be mediated by TLRs (7,63-67). Cytoplasmic danger 
sensing signals such as NODs are also involved in initiating inflammasome-mediated 
responses (68). For example, lipid molecules such as cholesterol crystals activate NLRP3 
inflammasome after TLR4 stimulation (69). Peptidoglycan released from gut microbiota 
could influence the innate immune system through NOD1 (6,69,70). Further, short-chain 
fatty acids produced by the gut modulate immune responses through G-protein coupled 
receptors such as GPR43 (6,69,70). These studies leave open the roles of other TLRs, and 
whether components of microbiota or metabolised nutrients are ligands for these receptors 
(6). Disruption of the normal interactions between gut microbiota and innate immune cells 
could alter the microbiota, promoting inflammation by signaling back to the innate immune 
system probably via pattern-recognition receptors such as TLRs resulting in metabolic 
dysfunction (6,48,63-67).  
 
In contrast to TLR2 & 4, mice lacking TLR5 exhibited increased adipose tissue mass 
combined with mild inflammation, reduced insulin sensitivity, elevated blood pressure, and 
increased circulating lipids compared to normal mice (48). Moreover, in TLR5 knockout 
mice, a high-fat diet accentuated metabolic dysfunction giving rise to fatty liver disease and 
Type 2 diabetes (48). Furthermore, transplanting gut microbiota from TLR5 knockout mice to 
normal germ-free mice induced the metabolic syndrome (48). TLR5 knockout mice also have 
increased food intake compared to normal mice (48). Crossing these mice with strains lacking 
other key immune system signaling did not change the phenotype of TLR5 knockout mice, 
suggesting that the metabolic dysfunction did not involve direct interactions between TLRs 
and other immune system signaling molecules (48,54). Which other signaling cascades could 
account for the metabolic dysfunction? In metabolic disease, redundant mechanisms may be 
initiated in order to limit exogenous nutrient intake and endogenous nutrient output, utilizing 
similar signaling molecules and pathways as in innate immunity. These changes may alter 
direct nutrient sensing in the brain probably through a gut-brain or gut-brain-liver axis via 
danger sensing signaling pathways. Saturated fatty acids may regulate hypothalamic function 
and hormone homeostasis in obesity through TLR/IκκB/NFκB signallng and endoplasmic 
reticulum stress (51,71). IκκB/NFκB activation in the hypothalamus increases food intake 
with impaired insulin and leptin signaling in mice fed a high-fat diet (51,71). Fatty acids such 
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as arachidonic acid induce TLR2 and 4 activation, initiating endoplasmic reticulum stress in 
the hypothalamus in rats (51,72). High-fat diet-induced anti-anorexigenic responses to leptin 
are reversed by TLR4 inhibiting antibody (51,72). Studies on neurodegenerative diseases also 
suggest that TLRs form an integral component in the communication between the CNS and 
the periphery (50). 
As mentioned, the CNS and immune system have been considered discrete entities with 
interaction between the two thought to be the result of dysfunctional systems (50). The brain, 
with a higher glucose demand but a lower minimal threshold for nutrient supply, engages 
mechanisms to respond to stress or nutritional starvation (19,25,50). These mechanisms could 
become dysfunctional during nutritional surplus as in obesity. In the brain, the TLRs are 
differentially expressed in neurons, astrocytes and microglial cells, at least at mRNA levels 
(50), with TLR2 and TLR4 being highly expressed (50,73,74). Microglia are the resident 
macrophages of the brain and express different TLRs (50), while astrocytes provide structural 
and metabolic support to neural tissue and express only TLR3 mRNA in humans and TLR 2, 
4, 5, and 9 mRNAs in mice (50.75). The mRNA for all TLRs has been detected in neurons in 
mice (76) but, as yet, only TLR3 (77) and TLR8 (78) mRNAs have been detected in humans. 
Schwann cells show relatively high expression of TLRs, especially 3, 4 and 7, suggesting 
they might act as sentinel cells in the peripheral nervous system (79). Bacterial lipoprotein 
ligands for TLR1 and TLR2 yield the strongest response in Schwann cells (79). Similar to 
Schwann cells, sciatic nerves express TLRs 3, 4, and 7 at basal levels, but upon axotomy, 
TLR1 becomes strongly induced compared to other TLRs, suggesting specialized receptor 
functions in basal and activated conditions of the peripheral nerve (79). mRNA expression 
was observed for TLRs 1-6 and 9, adapter proteins Md-1 and 2, and MYD88 in a study 
examining whether bacterial endotoxins that enter the intestinal interstitium could activate 
mouse colonic nociceptive dorsal root ganglion neurons (80). LPS induction increased 
neuronal excitability and expression and secretion of TNFα and IL1β from neurons (80). 
Further, systemic LPS administration induced inflammation in various regions of the brain 
(81). However, radiolabeling studies suggest that systemic administration of LPS gives rise to 
only limited LPS within the brain due to the blood-brain barrier prompting the suggestion that 
activation of the innate immune response in the brain may occur via peripheral activation of 
neural or endocrine networks that involve TLR4 (82). Thus, TLR signaling is an important 
component of the communication between the CNS and the periphery, including the intestine. 
More studies are required to address the unique roles of these receptors in regulating energy 
metabolism through neuronal feedback networks.  
Another class of cell-surface pattern-recognising receptors are G protein coupled receptors 
(GPCRs), which are involved in host immunity and many inflammatory diseases (83-85). 
Chemokines, complement products, and some cytokines act via GPCRs to trigger immune 
cell antimicrobial and/or inflammatory responses, but dysregulated GPCR expression or 
activation promotes disease (83-85). In obesity and metabolic disease, adipocyte stress and 
other functions such as lipolysis, fatty acid, and glucose uptake are modulated by 
inflammatory GPCRs and play a major role in inducing adiposity, chronic inflammation, and 
metabolic disease (3,86). We have identified a number of inflammatory GPCRs, including 
PAR2, C3aR, C5aR, and EP3 that play important functional roles in adipose biology, with 
their pharmacological inhibition preventing or treating diet-induced obesity and metabolic 
dysfunction in rats (87-89). Moreover, signaling through inflammatory GPCRs influences 
other innate immune signaling pathways through crosstalk with other receptors, including 
TLRs. For example, we recently characterised differential expression of about 100 GPCRs 
with LPS/TLR4 stimulation in human macrophages (90). Functionally, we showed 
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differential immune responses with co-activation of a GPCR, C5aR, and TLR4 in human 
monocytes and macrophages (91). Free fatty acids are ligands for some low-affinity GPCRs. 
We recently identified that dietary saturated fatty acids influence the expression of 
inflammatory GPCRs in both the mRNA and protein levels in immune cells such as 
macrophages (87). More detailed studies on the influence of dietary fats and crosstalk 
mechanisms are required as immune cells such as macrophages are highly motile and their 
activation state and their movement to specific organ types such as the adipose and liver 
could trigger an inflammatory state associated with obesity and metabolic disease. 
  
Energy storage, metabolism, immune cells and disease 
Many organ systems collaborate in recognition, absorption, storage, and metabolism of 
energy supply. The brain, brown and white adipose tissue, liver, skeletal muscle, and 
pancreas communicate to maintain energy homeostasis, regulating the balance between 
energy storage and metabolism when surplus energy is available. Once the food is recognized 
and absorbed in the intestine, the body initiates mechanisms to store or metabolize the 
nutrients in line with normal physiological needs. This process involves the body making a 
decision to store the nutrients, either as glycogen in tissues such as liver and muscle or as 
lipids in adipose tissue. Lipid-sensing processes such as fat synthesis, beta-oxidation, lipid 
transportation and distribution may be disturbed in obesity and metabolic dysfunction. In 
general, free fatty acids, lipoproteins, and chylomicrons determine which cells absorb lipids 
through specific membrane receptors for metabolism and storage.  
 
The activation of pattern recognition receptors can be dynamically modulated by metabolic 
products, by sensing the balance between saturated and unsaturated fatty acids in cellular and 
circulating lipids (51). For example, oxidized low-density lipoproteins and high blood 
glucose concentrations in diabetes enhance the expression and activation of TLR4 (51,92,93). 
In obesity, this disrupted lipid sensing can enhance the activation of these pattern recognition 
receptors in circulating leukocytes, particularly monocytes and macrophages, promoting 
tissue infiltration and a proinflammatory state (51). Both mammalian liver and adipose tissue, 
the major organs of storage and metabolism, have comparable structural blueprints in which 
metabolic cells such as hepatocytes and adipocytes are in close proximity to 
immunoregulatory cells such as Kupffer cells, macrophages, and T cells, with immediate 
access to a vast network of blood vessels (1,3). In the brain, neural tissues are in close 
proximity to microglial cells, which serve as resident macrophages (50). Such cellular 
proximity facilitates a continuous dynamic interaction between the immune and metabolic 
networks and affords the coordination of more distal sites such as the pancreatic islets and 
skeletal muscle (3). Thus, the immune system and the danger sensing system may integrate 
and process the signaling of these common biochemical and molecular nutrient and lipid-
sensing mechanisms at these sites to maintain or restore homeostasis.  
 
Adipose tissue 
Adipocytes are key cells in mammalian energy storage and metabolism. The central and 
autonomic nervous systems regulate whole body energy homeostasis, at least in part by 
modulating the metabolic and secretory activity of adipose tissue (94,95). Mammals have two 
main types of adipose tissue, white and brown, which store energy in the form of 
triglycerides and metabolize them to fatty acids. White adipose tissue provides these fatty 
acids to other tissues for normal physiological function. Brown adipose tissue plays a pivotal 
role in maintenance of body temperature by thermogenesis, and in protection against 
detrimental effects of surplus energy intake, which is regulated by the sympathetic nervous 
system (94,95). Neural feedback mechanisms, and possibly also the danger sensing system, 
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connect these adipose tissues to the brain which plays a major role in regulating energy 
homeostasis (94).  
 
White adipose tissue 
White adipocytes provide an important reversible storage depot for saving excess energy as 
lipids (3). In obesity, excessive white adipose tissue growth is associated with hypertrophy 
and hyperplasia of adipocytes (3). Excess energy intake or decreased expenditure results in 
excess triglyceride accumulation in white adipose tissue, which results in hypertrophy (3). 
Adipose tissue mass expands and redistributes throughout adult life, with proliferative 
adipocyte precursor cells standing ready to respond to increased demands for energy storage 
(3). Thus, hyperplasia results from recruitment of new adipocytes, involving proliferation and 
differentiation of pre-adipocytes (adipogenesis) (3). Adipocyte function can become 
compromised during storage of excess energy as fat (3) even though white adipocytes have 
an additional role to protect non-adipocytes from excessive fat intake and lipotoxicity (96). 
When there is continued nutritional surplus, the altered production of various endocrine, 
paracrine, and autocrine factors by mature white adipocytes is thought to play important roles 
in processes governing recruitment of new adipocytes as well as inflammatory cells such as 
macrophages. These processes may give rise to obesity together with ectopic fat deposition in 
liver, heart, muscle, and pancreatic beta cells that, in turn, leads to lipotoxicity and insulin 
resistance (3,96). The interactions between the systems regulating energy storage in 
adipocytes and adipose tissue with the danger sensing systems, most notably the 
macrophages, T cells, and mast cells that reside in or infiltrate the adipose tissue, are being 
investigated in a variety of rodent models of disease. These studies suggest that the signaling 
proteins secreted during energy storage and danger sensing can profoundly affect insulin 
sensitivity, triglyceride synthesis, and cardiovascular structure and function (3,5).  
 
White adipose tissue contains a resident population of innate immune cells, in particular 
macrophages and T lymphocytes that could sustain adipocyte dysfunction (3,97). These 
inflammatory cells are spatially and temporally associated with adiposity and may alter 
adipocyte secretory profiles (3,97). Alterations in both population and function of white 
adipose tissue T cells occur during early development of obesity but the triggers for this 
immune cell activation remain unknown (3,97). Most resident T cells in white adipose tissue 
of lean individuals are T regulatory (Treg) cells and T helper2 cells that, together with 
resident macrophages, produce IL10 and impede inflammation (3,97). Treg cells regulate 
innate immunity and express chemokine receptors that respond to cytokines produced by 
adipocytes (3,97). Conversely, the predominant resident T cells in white adipose tissue of 
obese individuals are T helper1 and CD8+ effector T cells (3,97). Similarly, the major 
resident macrophages in obese white adipose tissue are the classically activated 
proinflammatory M1 macrophages, which express F4/80, CD11c, and iNOS. However, 
adipose tissue in lean animals contains alternatively activated anti-inflammatory M2 
macrophages, which express F4/80, CD301, and Arg1 (98). In white adipose tissue of obese 
individuals, decreases in the number of Treg cells and the early appearance of CD8+ effector 
T cells, which assist infiltration of proinflammatory macrophages, together may disrupt 
adipocyte homeostasis and trigger an immune response that leads to further recruitment of 
circulating proinflammatory macrophages (3,97). This recruitment is then followed by 
macrophage activation, chemoattraction, and induction of the expression and release of 
cytokines and adhesion molecules (3,97). These inflammatory effectors from macrophages 
can act in a paracrine manner on adipocytes to stimulate other proinflammatory cytokines, 
macrophages, and adipokines and hence link inflammation to adipocyte dysfunction (3,97). 
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In a macrophage environment, pre-adipocytes can be effectively converted into macrophages, 
which suggests substantial cellular plasticity in adipocyte precursors (99). 
 
Macrophage infiltration of white adipose tissue during obesity alters expression of genes 
associated with danger sensing, including TLRs and complement components (3,98). The 
infiltration of macrophages to white adipose tissue was first reported in 2003, yet it is still not 
known whether a specific immune cell is chiefly responsible for metabolic dysfunction 
following macrophage infiltration in WAT in humans (97,100). Genetic knockout and DIO 
rodent studies suggest that macrophages, monocytes, leukocytes, platelets, T cells, Treg cells, 
and mast cells may contribute to development of metabolic diseases, particularly obesity and 
type 2 diabetes (3). Elevated free fatty acids in obesity can enhance activation of TLRs in 
adipocytes and immune cells (3,51). Human and animal studies show increased expression of 
TLR4 target genes, such as monocyte chemoattractant protein-1, TNFα, and IL6, in adipose 
and immune cells associated with obesity and insulin resistance (51). Further studies are 
necessary to tease out roles of individual immunoinflammatory cells in human metabolic 
dysfunction and to determine whether induced TLR signaling is local or systemic in origin. 
 
Further, in mice, weight loss induced by calorie restriction is associated with a rapid, 
temporary recruitment of macrophages to white adipose tissue, with remarkable similarities 
between the infiltrating macrophages found during weight loss and the cholesterol-laden 
macrophages found in atheromatous plaques (101). These observations lead to the prediction 
that the infiltrating macrophages may facilitate trafficking of lipids from the white adipose 
tissue to the liver for subsequent metabolism, a postulate that was supported by the transient 
recruitment patterns and the expression of scavenger receptors and lipid-handling genes 
(101). Mechanisms of macrophage regulation of white adipose tissue lipolysis in both rodents 
and humans remain unknown (101); further, whether macrophages exert endocrine or 
paracrine functions by transfer from macrophages to adipocytes is yet to be elucidated. 
However, it is clear that the sympathetic nervous system plays a major role as primary 
initiator of lipolysis in rodents and humans (102-104) and that immune cells and microglia 
interact with neurons, at least in many neurological disorders (49). Macrophages and mast 
cells are increased at the site of nerve injury, found close to primary nociceptive neurons, and 
contribute to nociceptor sensitization (49). Degranulation of mast cells also requires direct 
interaction between mast cells and peripheral nerve terminals (49). These immune cells are 
elevated in white adipose tissue in obese humans and may communicate with the brain to 
regulate lipolysis, thereby utilizing stored lipids for metabolism. Suppression or absence of 
mast cells by pharmacological inhibition, stabilization or genetic deficiency also prevents or 
treats diet-induced obesity in rodent models (105-107). Taken together, these studies suggest 
that, in addition to inducing local adipocyte inflammation, these immune cells may have 
distinct roles in regulating metabolism by communicating with the brain and peripheral 
tissues, but precisely how they communicate and alter metabolism still needs to be fully 
elucidated. 
 
Brown adipose tissue 
Brown adipose tissue plays a pivotal role in maintaining body temperature and protecting 
against detrimental effects of surplus energy intake (108). Brown adipose tissue uses fatty 
acids to produce heat, a process known as thermogenesis. Brown adipose tissue has been 
known for 500 years and it regulates cold-induced thermogenesis (109), but until recently 
other consequences of adaptive or diet-induced thermogenesis were unknown. Animal studies 
have shown that activation or expansion of brown adipose tissue prevents diet-induced 
weight gain and associated metabolic disorders (108). Diet-induced thermogenesis is the 
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physiological mechanism for dissipating excessive calorific intake as heat via brown adipose 
tissue and is regulated by the sympathetic nervous system (109,110). In obesity, varied 
susceptibility to diet-induced thermogenesis may account for differences in body weight gain 
by individuals in response to surplus energy (110).  Human therapeutics targeting the brown 
adipose tissue in metabolic disease have so far failed (111). However, an important question 
relevant to this review is whether brown adipose tissue regulates energy homeostasis and 
metabolism in obesity by communicating through nutrient and danger sensing systems.  
 
In other endocrine disorders such as hyperthyroidism, brown adipose tissue communicates 
with the hypothalamus using nutrient sensing enzymes, including AMP kinase, to regulate 
energy expenditure and body weight in rats (112,113). There is circumstantial evidence for 
involvement of the danger sensing system. Fatty acids mediate diet-induced thermogenesis 
(51), with polyunsaturated fatty acids causing greater induction than saturated fatty acids 
(110). Since danger sensing receptors can sense the balance between saturated and 
unsaturated fatty acids (51), it is possible that TLRs or their downstream components may 
modulate this change. Indeed, other traditional inflammatory components such as 
cyclooxygenase II, an important intermediate between lipids and inflammation, control 
energy homeostasis in mice by de novo recruitment of brown adipose tissue in white adipose 
tissue (114). Cyclooxygenase II is a downstream effector of beta-adrenoceptor signaling in 
white adipose and is required for induction of brown adipose in white adipose tissue depots 
(114). Noradrenaline from sympathetic nerves may induce cyclooxygenase II activity in 
white adipose and signaling downstream of PGI2/Ptgir/PPARg shifts the differentiation of 
mesenchymal progenitors from the stromovascular cells towards a brown adipose phenotype 
in white adipose tissue (114). This reinforces the idea that danger sensing mechanisms in an 
organism are interrelated with other energy-demanding processes, such as control of cellular 
energy supply. Of the prostanoids, PGI2 activates PPARδ and γ and induces adipogenesis and 
adipocyte differentiation, whereas PGE2 acts on EP3 receptors to decrease lipolysis by 
decreasing cAMP concentrations, thereby contributing to storage of fat in white adipocytes 
(3). This exemplifies at least two components of the traditional immune system playing 
opposing roles to regulate energy homeostasis, with PGI2 inducing brown adipose for energy 
consumption and PGE2 inducing white adipose tissue to store fat or energy. A more detailed 
understanding is needed of the communication between the danger sensing system and the 
sympathetic nervous system in brown adipose tissue. 
 
Other metabolic tissues  
Adipose tissue communicates with other organ systems such as liver, skeletal muscle, and 
pancreas to maintain energy homeostasis, regulating the balance between nutrient intake, 
storage and metabolism. Hormonal feedback loops such as glucagon, insulin, and incretins 
are well studied and enable communication between organ systems to regulate blood glucose 
and fatty acid concentrations. An important question is whether the danger sensing system 
plays similar regulatory roles via autocrine, paracrine, and neuroendocrine signaling 
networks. The presence and signaling of the danger sensing system in these metabolically 
relevant tissues suggests a more diverse role in regulating metabolism (51). Although 
inflammatory signaling in the liver during insulin resistance, obesity and fatty liver disease is 
well established (115-117), recent evidence suggests the presence of inflammatory signaling 
in skeletal muscle and pancreas (118-120). Studies on the underlying mechanisms that link 
metabolic dysfunction in obesity to the danger sensing system are still in their infancy. Until 
now, relatively few studies have focused on the roles of these receptors in the muscle and 
pancreas while the role of inflammatory mediators in liver disease is a rapidly expanding 
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field of research. This section will summarise the emerging roles for the danger sensing 
system in the liver, pancreas, and skeletal muscle. 
 
 
Liver 
The liver is the largest visceral organ in the body and is primarily responsible for metabolic 
regulation. Most of the blood leaving the absorptive surfaces of the digestive tract enters the 
hepatic portal system and flows into the liver, where liver cells extract the nutrients before the 
blood reaches the systemic circulation. Induction of immune cells and activation of 
inflammatory pathways during obesity leading to liver complications have been well-studied 
(115-117). Although lipid accumulation in liver may occur in pre-obese states without 
detectable systemic inflammation (11), obese patients without histopathological 
abnormalities in the liver display a low-grade expression signature of inflammatory genes; 
these livers could be more responsive to the TLR pathway (121). This study suggests that 
genes encoding chemokines and their respective receptors and cytokines involved in T-cell 
activation are increased and specific to the liver compared to visceral adipose tissue from 
these patients (121). Further, selective knockdown of TLR4 in hepatocytes prevents obesity-
induced inflammation and insulin resistance without affecting body weight in diet-induced 
obese mice (64). These findings support a hypothesis that inflammation, adiposity, and 
metabolic dysfunction do not necessarily initiate and perpetuate one another. Instead, energy-
regulatory processes (such as recognition, absorption, storage, and metabolism of host energy 
supply) utilize similar sets of signaling molecules and signaling pathways as in innate 
immune responses in order to maintain energy homeostasis. 
 
Pancreas 
Glucose is a major source of energy for all cells, particularly when stressed (e.g. ischaemia), 
so precise control over blood glucose concentrations by insulin, other hormones such as the 
incretins, and free fatty acids is essential. Impaired glucose tolerance is a delayed 
normalization of blood glucose concentrations after glucose intake, due to insufficiency of 
insulin or sometimes despite adequate insulin concentrations. Depending on systemic glucose 
and fatty acid concentrations, pancreatic beta cells are thought to regulate insulin secretion 
via the regulatory hormones. More recently, different fatty acids and inflammatory cytokines 
have been shown to regulate insulin secretion directly via endocrine, paracrine, and 
potentially autocrine mechanisms (122,123). Interleukin-22 was identified as a key anti-
inflammatory cytokine able to restore glucose homeostasis in mouse models of type 2 
diabetes by restoring insulin secretion from the pancreatic beta cells concomitant with 
reduced oxidative and endoplasmic reticulum stress (122). Increases in free fatty acids for 24 
to 48 hours also alter insulin gene expression and induce apoptosis in beta cells both in vitro 
and in vivo (124-126). Inflammatory signaling and mediators such as IL1β, TLRs, 
macrophages, and chemokines are elevated in pancreatic islets from patients with type 2 
diabetes (127). Increased glucose concentrations enhance free fatty acid-induced expression 
of inflammatory mediators in both human and mouse islets, suggesting that these responses 
are probably through an IL-1R/TLR dependent pathway (127). Activation of TLR4 in 
pancreatic beta cells affects insulin secretion in response to glucose in both humans and 
rodents (127). Although the expression and roles of TLR pathways in type 1 diabetes have 
been well characterized, details about their specialized roles in type 2 diabetes are not well 
understood.  
 
Skeletal muscle 
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Recent studies reveal that skeletal muscle is not a passive organ, but rather drives tolerance 
and elicits inflammatory signaling to foreign DNA and proteins (128). Similarly, in metabolic 
dysfunction, fatty acids can elicit inflammatory signaling to induce insulin resistance in 
muscle (118-120). Further, important roles have been proposed for resident skeletal muscle 
macrophages in muscle insulin resistance (118-120). In cultured muscle cells, conditioned 
media from palmitate-stimulated macrophages and other pro-inflammatory cytokines induce 
insulin resistance (128-130). This suggests that increased pro-inflammatory cytokines and 
saturated fatty acids in obesity can act on TLRs on muscle cells to regulate insulin 
responsiveness (128-131). Cytoplasmic danger sensing signaling such as NOD1 and NOD2 
are also expressed in muscle cells and activation of these receptors by saturated fatty acids 
induces insulin resistance in muscle (132). Taken together, these studies support roles for 
danger sensing signaling in regulating insulin sensitivity at the major sites of postprandial 
glucose utilization in the body.   
 
Human perspectives and concluding remarks 
Approaches to the treatment of Type 2 diabetes and obesity have provided significant insights 
into mechanisms of energy homeostasis. Current treatments to restore blood glucose 
concentrations and insulin sensitivity include insulin, metformin, sulphonylureas, 
thiazolidinediones, α-glucosidase inhibitors, incretin hormone-based therapies, and sodium-
dependent glucose co-transporter (SGLT) inhibitors (133). All of the above strategies 
improve glycemia and some even delay the onset of Type 2 diabetes. However, unfortunately 
none of the current therapeutic approaches seems to have disease-modifying characteristics 
that might result in slowing the progressive decline in insulin secretion (133). Furthermore, 
aggressive glucose control alone has not been shown to improve mortality from 
macrovascular causes, suggesting that the picture is more complex, likely involving elevated 
blood pressure, lipids, and inflammation. This hypothesis is supported by the significant 
impact on mortality of statin therapy, with some proportion of this benefit attributable to the 
off-target, anti-inflammatory actions of these widely used drugs.  
 
Nonetheless, a major observation from past and existing human therapies is the resilience of 
the human system to significant manipulation of body weight. A common feature of 
pharmacological approaches used to date, which include appetite suppression, reduction in 
gut nutrient intake, and renal glucose loss, is the consistent stabilization of weight after ~5% 
loss. Indeed, recent studies on the SGLT-2 inhibitors elegantly demonstrate that renal glucose 
loss is quickly matched by an increase in hepatic glucose intake (134), supporting our 
discussion above on multi-organ communication and sensing. Thiazolidinediones as a class 
also induce weight gain while improving glucose and insulin sensitivity (133). On the other 
hand, GLP1 and other incretins improve glycemia together with some reduction in body 
weight (133). 
 
Furthermore, achieving and maintaining weight loss is not necessarily the Holy Grail of 
therapeutic strategies for metabolic disease. Indeed, cardiovascular risk reduction in response 
to therapy can be explained and/or predicted using recognized risk factors such as BP and 
lipids, without weight. A central issue is to understand whether metabolic improvement with 
very little or no weight loss is achievable or desirable from a clinical perspective. Obesity 
without overt metabolic dysfunction (‘fit fat’) is not uncommon and, conversely, some lean 
people have severe metabolic disease (13). Some clinical studies suggest that systemic 
inflammation could determine the metabolic health status in obese and non-obese human 
patients (135). Decreased concentrations of many inflammatory mediators such as 
complement C3, CRP, TNF, IL6, PAI-1, 
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adiponectin concentrations correlate directly with metabolically healthy, but obese, 
individuals versus their metabolically unhealthy obese counterparts (135). Mechanistic 
evidence to date suggests that a minority (10-20%) of people are able to accommodate excess 
nutrients in adipose tissue by a process that relies mainly on generation of new fat cells as 
opposed to hypertrophy of existing fat cells (136). The former correlates with reduced 
adipose tissue inflammation and decreased ectopic fat in liver and muscle (136). It is unclear 
what the real drivers are in this compensatory process. Does early infiltration of inflammatory 
cells compromise adipogenesis, leading to defects in metabolic flexibility of adipose tissue 
and excess lipids entering other tissues such as liver, muscle and fat making them defective?  
Or, do intrinsic differences in differentiation capacity of preadipocytes initiate inflammatory 
and metabolic complications? In favour of the latter notion is the fact that isolation and long-
term culturing of preadipocytes from healthy obese versus unhealthy obese has revealed 
‘hard-wired’ changes in gene expression profiles consistent with the respective metabolic 
phenotypes (136). 
 
Thus, an ideal therapeutic strategy for human patients with Type 2 diabetes would not only 
restore glycemia, but would also prevent the progression of disease and the associated 
comorbidities such as cardiovascular, liver, and kidney diseases. As inflammation underlines 
most of these comorbidities, the aim of this review has been to highlight how targeting the 
immune system can not only restore glycemia but also prevent the progression of disease and 
the associated comorbidities. Finding new links between inflammation and metabolism 
promises a new and more detailed understanding of the interplay between immunity, 
nutrition, and energy homeostasis. Nutrient sensing and danger sensing systems in different 
organ systems share biochemical mediators and molecular mechanisms that maintain energy 
homeostasis and mediate immune responses. There is increasing evidence that dysfunctional 
autocrine, paracrine, and neuroendocrine signaling in these systems can lead to human 
obesity and metabolic dysfunction. Since both danger signaling and nutrient sensing modify 
metabolic function, some anti-inflammatory drugs, controlled dietary intake, and ‘smart’ 
designer foods might be expected to augment the immune system and peripheral 
neuroendocrine signaling thereby improving tolerance to surplus nutrients in obesity and 
restoring energy homeostasis. New studies designed to identify roles for specific signaling 
molecules shared by danger sensing and nutrient sensing pathways should aid the 
understanding of ways to modulate metabolism and immunity under either nutritional or 
immunological stress. Greater knowledge about how intersecting molecular signatures 
determine either good health or disease progression could lead to more rational choices of the 
most effective targets for therapeutic intervention in obesity, diabetes, inflammation, and 
cardiovascular diseases.    
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Figures 
 
 
Figure 1 – Communication between the brain, liver, adipose tissue, and gut in controlling 
appetite and energy homeostasis. The central nervous system processes complex 
information, including cognitive, visual, and olfactory cues to assess food palatability and 
both short- and long-term signals relating to changing nutritional status. Blood-borne and 
afferent neural regulatory signals including leptin, insulin, orexin, ghrelin, melanocortins, and 
neuropeptide Y communicate with the brain, liver, adipose tissue, and gut to adjust food 
intake and fat storage over time. The brain also communicates with adipose tissue in 
regulating storage and release of fatty acids – lipolysis. These organ systems may 
communicate with each other using non-hormonal mechanisms to regulate energy 
homeostasis, for example with the involvement of autocrine, paracrine, and neuroendocrine 
signaling of the danger sensing system. The working hypothesis is that disruption of this 
communication leads to the chronic inflammatory state seen in obesity and metabolic 
dysfunction. 
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Figure 2 – Role of immune sensing system in initiating metabolic dysfunction. The origin 
of inflammation in obesity and metabolic disease, either infectious or non-infectious or both, 
is still debatable. Activation of damage associated molecular patterns (DAMPs) due to tissue 
injury or pathogen associated molecular patterns (PAMPs) from the gut microbiota could lead 
to activation pattern recognizing receptors (PRRs) in other metabolic organs driving 
inflammation that underpins obesity and associated metabolic disease. 
 
  
